Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New research discusses how immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
A recent clinical trial found that the combination did not work.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.
Instead of researching new treatment targets or experimental combination therapies, she focuses on patient experience and quality of life.
The combination improved both overall survival and patient-reported outcomes.
Information for patients and caregivers on how to manage adverse events from immune checkpoint inhibitors
The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.
A third of people treated with the immunotherapy experienced remission.
A retrospective analysis showed that 29% of people with previously treated tumors responded to treatment.
Stay in touch with your cancer care team about how the new pandemic will affect you and your treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.